105 related articles for article (PubMed ID: 7979222)
1. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.
Vingerhoets FJ; Snow BJ; Lee CS; Schulzer M; Mak E; Calne DB
Ann Neurol; 1994 Nov; 36(5):759-64. PubMed ID: 7979222
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.
Vingerhoets FJ; Snow BJ; Tetrud JW; Langston JW; Schulzer M; Calne DB
Ann Neurol; 1994 Nov; 36(5):765-70. PubMed ID: 7979223
[TBL] [Abstract][Full Text] [Related]
3. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
Cordes M; Poewe W
Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
[TBL] [Abstract][Full Text] [Related]
4. Fluorodopa PET scanning in Parkinson's disease.
Snow BJ
Adv Neurol; 1996; 69():449-57. PubMed ID: 8615165
[TBL] [Abstract][Full Text] [Related]
5. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
Thobois S; Ribeiro MJ; Lohmann E; Dürr A; Pollak P; Rascol O; Guillouet S; Chapoy E; Costes N; Agid Y; Remy P; Brice A; Broussolle E;
Arch Neurol; 2003 May; 60(5):713-8. PubMed ID: 12756135
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
Hilker R; Schweitzer K; Coburger S; Ghaemi M; Weisenbach S; Jacobs AH; Rudolf J; Herholz K; Heiss WD
Arch Neurol; 2005 Mar; 62(3):378-82. PubMed ID: 15767502
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren.
Cordes M; Snow BJ; Cooper S; Schulzer M; Pate BD; Ruth TJ; Calne DB
Ann Neurol; 1994 Oct; 36(4):667-70. PubMed ID: 7944302
[TBL] [Abstract][Full Text] [Related]
8. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography.
Snow BJ; Bhatt M; Martin WR; Li D; Calne DB
J Neurol Neurosurg Psychiatry; 1991 Jan; 54(1):12-7. PubMed ID: 1901347
[TBL] [Abstract][Full Text] [Related]
9. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.
Snow BJ; Tooyama I; McGeer EG; Yamada T; Calne DB; Takahashi H; Kimura H
Ann Neurol; 1993 Sep; 34(3):324-30. PubMed ID: 8363349
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning.
Takahashi H; Snow BJ; Bhatt MH; Peppard R; Eisen A; Calne DB
Lancet; 1993 Oct; 342(8878):1016-8. PubMed ID: 8105264
[TBL] [Abstract][Full Text] [Related]
11. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa.
Boecker H; Weindl A; Leenders K; Antonini A; Kuwert T; Kruggel F; Grafin von Einsiedel H; Conrad B
Acta Neurol Scand; 1996 Jun; 93(6):387-92. PubMed ID: 8836298
[TBL] [Abstract][Full Text] [Related]
12. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.
Takikawa S; Dhawan V; Chaly T; Robeson W; Dahl R; Zanzi I; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1994 Jun; 35(6):955-63. PubMed ID: 8195882
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia.
Nygaard TG; Takahashi H; Heiman GA; Snow BJ; Fahn S; Calne DB
Ann Neurol; 1992 Nov; 32(5):603-8. PubMed ID: 1449240
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease.
Vingerhoets FJ; Schulzer M; Ruth TJ; Holden JE; Snow BJ
J Nucl Med; 1996 Mar; 37(3):421-6. PubMed ID: 8772636
[TBL] [Abstract][Full Text] [Related]
15. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
[TBL] [Abstract][Full Text] [Related]
16. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.
Pate BD; Kawamata T; Yamada T; McGeer EG; Hewitt KA; Snow BJ; Ruth TJ; Calne DB
Ann Neurol; 1993 Sep; 34(3):331-8. PubMed ID: 8363350
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism.
Snow BJ; Nygaard TG; Takahashi H; Calne DB
Ann Neurol; 1993 Nov; 34(5):733-8. PubMed ID: 8239569
[TBL] [Abstract][Full Text] [Related]
18. Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia.
Calne DB; de la Fuente-Fernández R; Kishore A
J Neural Transm Suppl; 1997; 50():47-52. PubMed ID: 9120424
[TBL] [Abstract][Full Text] [Related]
19. The rate of progression of Parkinson's disease.
Sawle GV
Ann Neurol; 1992 Feb; 31(2):229. PubMed ID: 1575462
[No Abstract] [Full Text] [Related]
20. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow.
Bhatt MH; Snow BJ; Martin WR; Pate BD; Ruth TJ; Calne DB
Ann Neurol; 1991 Jun; 29(6):673-7. PubMed ID: 1892369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
